Labiotech.eu

News and Trends 7 Nov 2022

First patient dose completed for bladder cancer diagnostic drug

Asieris Pharmaceuticals says it has completed the first patient dose in its phase III bridging trial for Hexvix, a drug used for the diagnosis of bladder cancer. Asieris Pharmaceuticals is a global biopharmaceutical company specializing in the discovery and development of drugs for the treatment of genitourinary tumors and other major diseases. The study is a […]

November 7, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 4 Nov 2022

EMPA-KIDNEY trial meets primary endpoint in trial for drug to treat chronic kidney disease

A phase 3 clinical trial, EMPA-KIDNEY, met its primary endpoint showing a significant kidney and cardiovascular benefit for adults living with chronic kidney disease (CKD). When treated with Jardiance (empagliflozin), the risk of kidney disease progression or cardiovascular death was significantly reduced by 28% versus placebo. The results were announced today during the American Society of […]

November 4, 2022 - 4 minutesmins - By Liza Laws

More News! 4 Nov 2022

Sanofi and AstraZeneca drug, Beyfortus, for RSV in babies and children approved

A drug being developed jointly by Sanofi and AstraZeneca for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants was approved today (November 4). The European Commission has approved Beyfortus which is so far the first and only broadly protective option against the virus. Thomas Triomphe, executive vice president, […]

November 4, 2022 - 2 minutesmins - By Liza Laws

More News! 4 Nov 2022

Optibrium and Lhasa Limited study published on predictive modelling for enzymes

A peer reviewed study published in the Journal of Medicinal Chemistry has been published by Optibrium and Lhasa Limited that shows advance predictive modelling for drug-metabolizing enzymes. The companies are two of the leading developers of software and artificial intelligence (AI) solutions for drug discovery and development. In the paper, ‘Predicting Regioselectivity of AO, CYP, […]

November 4, 2022 - 3 minutesmins - By Liza Laws

centogene rare diseases diagnostic ipo nasdaq

News and Trends 4 Nov 2022

Centogene launches rare and neurodegenerative disease Biodata Network

German company, Centogene N.V., today (November 4) announced its launch of Biodata Network, a portfolio of data-driven partnering solutions including licenses and insight report for biopharma and research institutions. The company, which works to find data-driven answers in rare and neurodegenerative diseases, wants to offer increased access to its insights. To do this, it has […]

November 4, 2022 - 3 minutesmins - By Liza Laws

News and Trends 4 Nov 2022

Creative Medical Technology Holdings announces FDA clearance of diabetes drug

Creative Medical Technology Holdings yesterday (November 3) announced its investigational new drug (IND) application has been cleared by the U.S. Food and Drug Administration (FDA). This will enable the company to start initiating a clinical trial for type 1 diabetes using AlloStem. The primary objective of the study is to evaluate Allostem in patients with […]

November 4, 2022 - 3 minutesmins - By Liza Laws

More News! 4 Nov 2022

Alimentiv and Summit collaborate to tackle liver disease NASH

Drug development programs will be driven forward by a collaboration between Alimentiv Inc. and Summit Clinical Research, in a bid to tackle non-alcoholic steatohepatitis (NASH). They announced a strategic alliance to tackle the now growing global epidemic with no approved treatments. It says that current challenges include optimizing and end-point assessment, minimizing screen failures and […]

November 4, 2022 - 3 minutesmins - By Liza Laws

News and Trends 4 Nov 2022

A new weapon against antibiotic-resistant bacteria?

Is edoxudine, an anti-herpes molecule discovered in the 60s, effective against Klebsiella pneumoniae, a common bacterium in hospitals? The excessive use of antibiotics has pushed bacteria to develop resistance mechanisms to treatment. Antibiotic resistance is now considered by the WHO as one of the greatest threats to health. The lack of treatment against multi-resistant bacteria […]

November 4, 2022 - 3 minutesmins - By Jim Cornall

Best in Biotech 4 Nov 2022

Get to know 15 of the best biotech companies in Paris

Paris may attract tourist masses, but it also attracts a lot of biotech enthusiasts. In this guide, we explore 15 interesting biotech companies in Paris. Paris is one of the biggest biotech clusters in Europe, with a wide range of applications being developed from drug discovery and medical devices to synthetic biology and green energy. […]

November 4, 2022 - 11 minutesmins - By Omnia Ibrahim

News and Trends 4 Nov 2022

Novadip Biosciences raises €40M for bone defect treatments

Novadip Biosciences has raised an additional €40 million ($39.2 million) in a series B equity round and non-dilutive funding. The clinical-stage biopharma company is developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment. The funding will accelerate the clinical development of two of […]

November 4, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 4 Nov 2022

Beyond Biotech podcast 21: CanSinoBIO, HTID, Longevity Science Foundation

This week, we have three interviews, and four guests. We chat with Pierre Corneille VP of the HTFC, which is responsible for HealthTech Innovation Days; Sergey Jakimov, co-founder and managing partner of LongeVC and the Longevity Science Foundation’s CEO Lisa Ireland; and Pierre Morgon, executive vice president of CanSinoBIO. We also have our weekly contribution […]

November 4, 2022

News and Trends 4 Nov 2022

Companies with exclusive rights to CRISPR diagnostic methods sign agreement

Two companies with sole rights to two CRISPR diagnostic methods in markets outside the U.S. and Greater China have signed a licensing agreement. Sherlock Biosciences announced today (November 3) that it has signed a deal with China-based Tolo Biotech which grants co-exclusive rights to the Cas12 and Cas13 method patents. As the only two companies […]

November 4, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

First patient dose completed for bladder cancer diagnostic drug

EMPA-KIDNEY trial meets primary endpoint in trial for drug to treat chronic kidney disease

Sanofi and AstraZeneca drug, Beyfortus, for RSV in babies and children approved

Optibrium and Lhasa Limited study published on predictive modelling for enzymes

Centogene launches rare and neurodegenerative disease Biodata Network

Creative Medical Technology Holdings announces FDA clearance of diabetes drug

Alimentiv and Summit collaborate to tackle liver disease NASH

A new weapon against antibiotic-resistant bacteria?

Get to know 15 of the best biotech companies in Paris

Novadip Biosciences raises €40M for bone defect treatments

Beyond Biotech podcast 21: CanSinoBIO, HTID, Longevity Science Foundation

Companies with exclusive rights to CRISPR diagnostic methods sign agreement

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!